SCHEMBL1744681

SCHEMBL1744681

COC(=O)CCc1ccc(O[C@@H]2CCc3ccccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 4/20 0.52
ALDH1A1 P00352 2/20 0.45
GFRA2 O00451 1/20 0.44
GFRA3 O60609 1/20 0.44
KDM4E B2RXH2 1/20 0.43
ADRB2 P07550 1/20 0.42
ADRB1 P08588 1/20 0.42
MAPT P10636 2/20 0.41
NPC1 O15118 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADRA1D P25100 1/20 0.41
ADRA1A P35348 1/20 0.41
ADRA1B P35368 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
IDO1 P14902 1/20 0.40
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745225 1.00 FFAR1 (0.52) FFAR1ALDH1A1GFRA2GFRA3KDM4E
SCHEMBL1744692 1.00 FFAR1 (0.52) FFAR1ALDH1A1GFRA2GFRA3KDM4E
SCHEMBL1746463 0.93 FFAR1 (0.53) FFAR1ALDH1A1KDM4EADRB2ADRB1
SCHEMBL1747359 0.93 FFAR1 (0.51) FFAR1ALDH1A1GFRA2GFRA3KDM4E
SCHEMBL1745194 0.88 FFAR1 (0.54) FFAR1ALDH1A1GFRA2GFRA3KDM4E
SCHEMBL1744984 0.87 MTNR1A (0.50)
SCHEMBL1744583 0.87 GFRA3 (0.49) FFAR1GFRA2GFRA3
SCHEMBL1633343 0.86 FFAR1 (0.57) FFAR1
SCHEMBL1745432 0.86 FFAR1 (0.57) FFAR1
SCHEMBL1633344 0.86 FFAR1 (0.57) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885ALDH1A1 4258/4885GFRA2 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.